ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0608

Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients

Valerie Umaefulam1, Terri-Lynn Fox1, Glen Hazlewood1, Nick Bansback2, Claire Barber1 and Cheryl Barnabe1, 1University of Calgary, Calgary, AB, Canada, 2University of British Columbia, Vancouver, BC, Canada

Meeting: ACR Convergence 2021

Keywords: Indigenous, Patient decision aid, race/ethnicity, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Healthcare Disparities in Rheumatology Poster (0594–0622)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Patient decision aids (PtDA) can enable shared decision-making between patients and healthcare providers. We have previously developed a PtDA for first-line methotrexate-based treatment options in rheumatoid arthritis (RA). Adaptations to PtDAs for use with populations facing inequities in healthcare can improve the relevancy of information presented, incorporate appropriate cultural context, and address health literacy concerns. Our objective was to adapt the Early RA PtDA for use with Canadian Indigenous patients making initial disease-modifying treatment choices.

Methods: The Early RA PtDA was modified through an iterative process using data obtained from semi-structured interviews with Indigenous patients with RA using an interview guide. A thematic analysis of interview transcriptions was completed using NVivo 12 software. Initial modifications were made based on the input of a first cohort of patients, with the revised Early RA PtDA verified by a second cohort of patients.

Results: The initial directions for modification were provided by 7 participants, while 9 participants were recruited for the verification cohort. All participants were women living with RA and self-identified as First Nations, Plains Cree, or Indigenous. In the first iteration, the revisions made were to 1) clarify medication names and routes of administration; 2) include Indigenous traditional healing practice options; 3) provide information on formulary coverage for Indigenous patients; 4) simplify text; and 5) include Indigenous images, and use colors aligned with Canadian Indigenous community representation. The second cohort perceived the revised Early RA PtDA to be acceptable for layout and information content, with appreciation expressed by participants for including Indigenous traditional healing practices as adjuncts to treatment, which was seen as beneficial for advancing communication and relationship building with health practitioners. Additional revisions were requested to increase text legibility, insert more Indigenous images, make further changes in colors, address formulary coverage for non-status First Nations patients, and include information on lifestyle factors in managing RA. Indigenous patient-specific evidence on the efficacy and safety of medication options should be included in future iterations if data available, and translation of key words into the end-users’ Indigenous languages should be included for implementation of the PtDA.

Conclusion: Incorporating Indigenous-specific adaptations in the design of PtDAs may increase use and relevancy to support patient focused care and engagement in treatment decisions, thereby supporting health-equity oriented health service interventions.

Adapted Early RA Decision Aid for Indigenous Patient Use (Page 1)

Adapted Early RA Decision Aid for Indigenous Patient Use (Page 2)


Disclosures: V. Umaefulam, None; T. Fox, None; G. Hazlewood, None; N. Bansback, None; C. Barber, None; C. Barnabe, Pfizer, 1, Gilead, 1, Novartis, 6, Sanofi, 6, Celltrion, 1.

To cite this abstract in AMA style:

Umaefulam V, Fox T, Hazlewood G, Bansback N, Barber C, Barnabe C. Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/adaptation-of-a-shared-decision-making-tool-for-early-rheumatoid-arthritis-treatment-decisions-with-indigenous-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adaptation-of-a-shared-decision-making-tool-for-early-rheumatoid-arthritis-treatment-decisions-with-indigenous-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology